Table 1.
Characteristics of included studies
| EF | |||||||
|---|---|---|---|---|---|---|---|
| Study | N | Centre/country | Setting | Levosimendan | Control | Levosimendan dosage | Control |
| Landoni 2017 | 506 | Multicenter/Italy | CABG or HVR | 50 (37–59) | 50 (40–60) | Bolus: none Inf: 0.025 to 0.2 ug/kg/min Duration: 48 h |
Placebo |
| Mehta 2017 | 849 | Multicenter/USA | CABG or HVR | 26 (24–32) | 27 (22–31) | Bolus: 0.2 ug/kg/min. Inf: 0.1 ug/kg/min Duration: 24 h |
Placebo |
| Cholley 2017 | 335 | Multicenter/French | CABG or HVR | <40% | < 40% | Bolus: none Inf: 0.1ug/kg/min Duration: 24 h |
Placebo |
| Anastasiadis 2016 | 32 | Single/Greece | CABG or HVR | 35.7 ± 4.9 | 37.5 ± 3.4 | Bolus: none Inf: 0.1ug/kg/min Duration: 24 h |
Placebo |
| Baysal 2014 | 128 | Single/Turkey | HVR | 35.0 (20–45) | 35 (25–45) | Bolus: 6ug/kg Inf: 0.1 ug/kg/min Duration: 24 h |
Standard therapy |
| Erb 2014 | 33 | Single/Germany | CABG or HVR | 22.0 ± 4.5 | 22.4 ± 5.5 | Bolus: none Inf: 0.1 ug/kg/min Duration:24 h |
Placebo |
| Levin 2012 | 252 | Single/USA | CABG | < 25% | < 25% | Bolus:10ug/kg Inf: 0.1 ug/kg/min Duration:24 h |
Placebo |
| Lomivorotov 2012 | 60 | Single/Russia | CABG | 28.8 ± 4.0 | 27.8 ± 5.4 | Bolus:12ug/kg Inf: 0.1 to 0.2 ug/kg/min Duration: 24 h |
IABP |
| Lahtinen 2011 | 200 | Single/Finland | CABG or HVR | More than 50% | More than 50% | Bolus: 24ug/kg Inf: 0.2 ug/kg/min Duration: 24 h |
Placebo |
| Tritapepe 2009 | 102 | Single/Italy | CABG | 41.6 ± 10.7 | 44.1 ± 9.8 | Bolus: 24 ug/kg Duration: 10 min |
Placebo |
| De Hert 2007 | 30 | Single/Belgium | CABG | 24 ± 6 | 27 ± 3 | Bolus: none Inf: 0.1 ug/kg/min Duration: 24 h |
Placebo |
| Tritapepe 2006 | 24 | Single/Italy | CABG | 50 ± 7 | 52 ± 5 | Bolus: 24 ug/kg Duration: 10 min |
Placebo |
| Al-Shawaf 2006 | 30 | Single/Kuwait | CABG | 29 ± 6 | 31 ± 6 | Bolus: 12ug/kg Inf: 0.1 ug/kg/min Duration: 24 h |
Placebo |
| Eriksson 2009 | 60 | Multicenter/Finland | CABG | 36 ± 8 | 36 ± 8 | Bolus: 12 ug/kg Inf: 0.2 ug/kg/min Duration: 24 h |
Placebo |
| Leppikangas 2011 | 24 | Single/Finland | CABG or HVR | 63 ± 9 | 69 ± 9 | Bolus: 12 ug/kg Inf: 0.2 ug/kg/min Duration: 24 h |
Placebo |
| Alvarez 2006 | 41 | Single/Spain | CABG or HVR | 35.5 ± 4.2 | 33.2 ± 5.2 | Bolus: 12ug/kg Inf: 0.2 ug/kg/min Duration: 24 h |
Dobutamine |
| Shah 2014 | 50 | Single/India | CABG | 22.5 ± 4.1 | 22.6 ± 3.4 | Bolus: none Inf: 0.13 ug/kg/min Duration: 24 h |
Placebo |
CABG coronary artery bypass grafting, HVR heart valve replacement, EF ejection fraction, IABP intra-aortic balloon counterpulsation, Inf infusion, USA United States of America